368
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

ORCID Icon, ORCID Icon, ORCID Icon, , , , , ORCID Icon, & show all
Pages 1041-1054 | Published online: 08 Mar 2021

Figures & data

Table 1 Healthcare Provider (HCP) Survey (n=501)

Table 2 Demographic and Clinical Characteristics in the Pre-Index Period Among Patients with DED Treated with Lifitegrast (n=600)

Table 3 Lifitegrast Utilization Among Patients with DED

Figure 1 Proportion of patients with DED-related treatments in the 6-month pre-index period and added to lifitegrast in the post-index period (n=600)*. Vertical bars indicate 95% confidence intervals. Patients may have multiple DED-related treatments; therefore, the sum of percentages may exceed 100%. *11 patients (1.8%) switched from lifitegrast to other therapies during the post-index period. These patients are not included in .

Figure 1 Proportion of patients with DED-related treatments in the 6-month pre-index period and added to lifitegrast in the post-index period (n=600)*. Vertical bars indicate 95% confidence intervals. Patients may have multiple DED-related treatments; therefore, the sum of percentages may exceed 100%. *11 patients (1.8%) switched from lifitegrast to other therapies during the post-index period. These patients are not included in Figure 1.

Table 4 Patients with DED Symptoms Reported in the Pre- and Post-Index Periods

Table 5 DED Questionnaires in the Pre- and Post-Index Periods

Table 6 DED Sign Assessments in the Pre- and Post-Index Periods